Fate of lymphocytes after withdrawal of tofacitinib treatment.
Tofacitinib (Tofa) is an inhibitor of Janus Kinase 3, developed for the treatment of autoimmune diseases and for the prevention of transplant rejection. Due to its selective action on proliferating cells, Tofa can offer a way to block T cell activation, without toxic effects on resting cells. Howeve...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Public Library of Science (PLoS)
2014
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/c368fa2460f142dba23c19f4c39d15f0 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|